CD44 is a widely expressed, multifunctional, cell-surface glycoprotein that has been implicated in the regulation of normal hematopoiesis. In addition, expression of particular isoforms of CD44 has been associated with malignant transformation and/or the acquisition of metastatic potential. In this study, we used two recently developed monoclonal anti-CD44 antibodies, one reactive with an epitope shared by many CD44 isoforms and the other with an epitope unique t o CD44 isoforms containing amino acids encoded by the alternatively spliced exon v10, t o compare the expression of CD44 on primitive hematopoietic cells from the marrow of normal individuals and their neoplastic counterparts present in the peripheral blood of patients with chronic myeloid leukemia (CML). Multiparameter fluorescence-activated cell sorter (FACS) analysis and cell sorting studies showed that CD44 is normally expressed at high t o very high levels on both long-term culture-initiating cells (LTC-IC) and granulopoietic colony-forming cells (granulocyte-macrophage colony-forming units [CFU-GM]). In contrast, primitive erythropoietic progenitors (burst-forming units-erythroid [BFU-El) in normal marrow were more homogeneous in their expression of CD44, and very few (less N ADULT LIFE, THE proliferation and differentiation of primitive hematopoietic progenitors is normally restricted to the bone marrow, where these cells interact with various stromal cells of nonhematopoietic origin, as well as with a complex mixture of extracellular matrix (ECM) components. Such interactions are believed to regulate the accessibility of these cells to stimuli that control their viability, cell-cycle progression, and movement into and out of the circulation. These concepts are based in part on the identification on the surface of primitive hematopoietic cells of cytokine receptors and adhesion molecules with affinities for various membrane or ECM-bound ligands.',' In addition, in vivo experiments have shown that particular ligands, or antibodies for specific cell adhesion molecules, may stimulate the rapid exodus of primitive hematopoietic cells from the marrow into the blood or, conversely, may alter the showed the presence of two exon vl0-containing mRNA species. In CML, a significantly greater proportion of the circulating neoplastic CFU-GM expressed very high levels of CD44. and these CFU-GM were accompanied by an increased number of light density v10' cells, including some that coexpressed CD34. Nonmalignant hematopoietic progenitors mobilized by prior chemotherapy and growth factor treatment of patients with Hodgkin's disease or acute myeloid leukemia in remission showed no changes in CD44 expression relative t o normal marrow progenitors. These results provide evidence of early differentiation-associated changes in CD44 expression during normal hematopoiesis in vivo that may be deregulated in the neoplastic clone of patients with CML.
N ADULT LIFE, THE proliferation and differentiation of primitive hematopoietic progenitors is normally restricted to the bone marrow, where these cells interact with various stromal cells of nonhematopoietic origin, as well as with a complex mixture of extracellular matrix (ECM) components. Such interactions are believed to regulate the accessibility of these cells to stimuli that control their viability, cell-cycle progression, and movement into and out of the circulation. These concepts are based in part on the identification on the surface of primitive hematopoietic cells of cytokine receptors and adhesion molecules with affinities for various membrane or ECM-bound ligands.',' In addition, in vivo experiments have shown that particular ligands, or antibodies for specific cell adhesion molecules, may stimulate the rapid exodus of primitive hematopoietic cells from the marrow into the blood or, conversely, may alter the showed the presence of two exon vl0-containing mRNA species. In CML, a significantly greater proportion of the circulating neoplastic CFU-GM expressed very high levels of CD44. and these CFU-GM were accompanied by an increased number of light density v10' cells, including some that coexpressed CD34. Nonmalignant hematopoietic progenitors mobilized by prior chemotherapy and growth factor treatment of patients with Hodgkin's disease or acute myeloid leukemia in remission showed no changes in CD44 expression relative t o normal marrow progenitors. These results provide evidence of early differentiation-associated changes in CD44 expression during normal hematopoiesis in vivo that may be deregulated in the neoplastic clone of patients with CML. 0 1995 by The American Society of Hematology.
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homing of primitive hematopoietic cells into the Neoplastic transformation may also alter the adhesive characteristics of primitive hematopoietic cells with associated changes in their turnover and tissue distribution. For example, in chronic myeloid leukemia (CML), a multilineage clonal malignancy believed to arise as a result of the formation of a BCR-ABL fusion gene in a pluripotent hematopoietic stem cell,' the leukemic progenitors exhibit abnormal adhesive properties, are found at abnormally elevated levels in the blood, and are able to establish hematopoiesis in extramedullary sites.'." CD44 is an adhesion molecule that is expressed on the surface of many cells, including representatives of all hematopoietic cell lineages."-16 Hyaluronan is the most widely recognized ligand of CD44, but evidence of binding to fibronectin, collagen, and serglycin has also been rep~rted.''.'~ The common form of CD44 expressed on hematopoietic cells (CD44H) is an 85-to 90-kD glycoprotein. A large number of higher-molecular-weight isoforms may also be produced in specific cell types or under specific conditions as a result of the alternative splicing of at least 10 contiguous exons (v1 through v10) within the CD44 gene.'"'" CD44R1 is one of several vl0-containing CD44 cDNAs. It was cloned from the KG-1 a leukemic cell line and contains in the extracellular region of the molecule an insertion of 132 amino acids encoded by exons v8, v9, and v10." This isoform corresponds to domains IV and V of the original CD44 clones and to the epithelial form of CD44 (CD44E), from which it differs by only three amino acids." CD44R2 (also referred to as domain V) is a vl0-containing isoform of CD44 that shares only the last 69 amino acids present in the unique region of CD44R1. Both the expression and binding properties of CD44 on normal cells appear to be subject to regulation. ' sion have been found to characterize various metastasizing cells, such as those present in certain aggressive lymphot i o n~. *~-~~ Evidence that CD44 may be involved in the regulation of early stages of normal hematopoiesis has been suggested by the observations that primitive clonogenic cells express CD44I5 and that the addition of anti-CD44 monoclonal antibodies to long-term marrow cultures (LTC) can cause a marked and sustained decrease in the number of mature cells subsequently found in the nonadherent fraction of these ~u l t u r e s .~~~~' Whether this is due to an effect on the primitive hematopoietic cells that normally become part of the adherent cell layer in this culture system has not been established. Indeed, the level of expression of CD44 on cells that give rise to clonogenic progenitors under these conditions in vitro has not been previously characterized. Similarly, in spite of the well-known abnormal adhesive properties of CML cells, potential alterations in their expression of CD44 have not been investigated.
In this study, we show that there are quantitative differences in the levels of CD44 expressed on primitive normal erythroid (burst-forming unit-erythroid [BFU-E]) and granulopoietic (colony-forming unit-granulocyte/macrophage [CFU-GM]) progenitors and on their precursors identified functionally as LTC-initiating cells (LTC-IC). We have also identified a small subset of CD34-cells in normal marrow that express CD44 isoform(s) containing the amino acids encoded by the alternatively spliced exon v10. Interestingly, quantitative changes in both of these aspects of CD44 expression were found when predominantly leukemic populations isolated from patients with CML were studied. These changes include an increase in the proportion of CFU-GM expressing very high levels of CD44 and the expression of the exon vl0-containing CD44 isoform(s) on CD34' neoplastic cells.
mas23-25 and in a variety of transformed epithelial cell popula-
MATERIALS AND METHODS
Cells. All samples of human peripheral blood (PB) and bone marrow (BM) were obtained from informed and consenting individuals. Samples of normal BM were from harvests taken for allogeneic transplantation or from normal cadaveric tissue. Some samples were also obtained from leukapheresis harvests collected from patients with hematologic diseases in remission (two with Hodgkin's disease and one acute myeloid leukemia [AML]). The two patients with Hodgkin's disease received chemotherapy (cyclophosphamide, 7 g/ m' ) followed by administration of interleukin-3 (IL-3; 2.5 to 5 pgi' kg/d) and granulocyte-macrophage colony-stimulating factor (GM-C S F 5 pgkgld) until the leukaphereses were completed. The patient with AML received G-CSF (12 pg/kg/d) for 5 days followed by 2 days of leukapheresis. Heparinized PB samples were obtained from patients with newly diagnosed Philadelphia chromosome-positive (Ph') chronic phase CML undergoing routine hematologic assessment ( Table 1) . In all but one case, the CML cells had been cryopreserved in 90% fetal calf serum (FCS; StemCell Technologies, Vancouver, Canada) and 10% dimethyl sulfoxide and then stored at -70°C before use. To ensure that the results of analyses of CML samples could be attributed to leukemic progenitor populations, only PB samples that were found to contain clonogenic cells that were present at frequencies at least 25-fold above the mean for fresh normal blood were used ( Table 1 ). All analyses were performed on cells in the light-density fraction (less than 1.077 g/mL) isolated using Ficoll-hypaque (Pharmacia LKB, Uppsala, Sweden).
Antibodies. lgGl monoclonal antibodies (MoAbs) specific for CD34 (8G12),32 Thy-l (5E10),33 and an epitope located on the common NH,-terminal region of different isoforms of CD44 (3C12))4 were purified from tissue culture supernatants using Protein G chromatography (Pharmacia LKB). MoAb 8G12 labeled with Cyanine-5 (Cy5) has been described previously32 and was used at 10 pg/mL. quences located in the 5' common region and in the 3' alternatively spliced exon v10 were used: 5'(5'-TGTACATCAGTCACA-GACCT-3') and ~'(S-AGGAACGATTCIACATTAGAG-~'). Total RNA was isolated using TRIzol Reagent (Gibco BRL, Gaithersburg, MD). The first cDNA strand was generated in a 50-pL reaction containing 5 pg of total RNA, 0.5 mmol/L deoxynucleotide triphosphates (dNTPs), 200 pm01 of random hexamers, 4 mmol/L dithiothreitol, 200 U of superscript reverse transcriptase (Gibco BRL), and 2.5 U of human placental RNase inhibitor (Gibco BRL). The reaction was incubated at 42°C for 1 hour followed by 5 minutes at 95°C to inactivate the enzyme. Then I O pL of this reaction was subjected to PCR in a 100-pL volume of 25 mmol/L KCI, 1.5 mmol/L MgC12, 0.2 mmol/L dNTPs, 1 0 0 pmol of each primer, and 2.5 U of Taq polymerase, Thirty cycles were performed as follows: 30 seconds of denaturation at 94°C. 30 seconds of annealing at 48°C. and 3 minutes of extension at 72°C. This was followed by a final extension at 72°C for 5 minutes. The PCR products were separated on a 2% agarose gel, transferred to a nylon membrane, and hybridized to a 196-bp vl0-specific probe obtained by PCR of the CD44R1 cDNA2' using the primers 5'(5'-TAGGAATGATGTCACAGGTG-3') and 3'(5'-AGGAACGATTGACATTAGAG-3'). Hybridization was performed overnight at 60°C in 6X saline sodium citrate (SSC; 1 X SSC is 0. I5 mol/L NaCI, 0.01 5 mol/L sodium citrate, pH 7.5). 1 % sodium dodecyl sulfate (SDS), 0.02% polyvinylpyrrolidone, 0.02% ficoll, 0.02% bovine serum albumin (BSA), 10 pg/mL of denatured salmon sperm DNA, and 10' c p d m l of denatured probe. The filter was then washed at a final concentration of 0.1 X SSC, 1% SDS at 65°C. Autoradiography was performed at room temperature with Kodak XAR-5 film for 14 hours (Eastman-Kodak, Rochester, NY). Hematopoietic progenitor assays. Cells from primary samples or LTC harvests were assayed for clonogenic erythropoietic (BFU-E), granulopoietic (CFU-GM), and multilineage (CFU-granulocyte, erythroid, monocyte, megakaryocyte: CFU-GEMM) progenitors in Iscove's DMEM-based methylcellulose cultures containing 3 UlmL of human erythropoietin; 20 n g h L each of granulocyte colonystimulating factor (G-CSF; Amgen, Thousand Oaks, CA), granulocyte-macrophage CSF (GM-CSF; Sandoz, Basel, Switzerland), IL-3 (Sandoz), and IL-6 (obtained from the supernatant of COS cells transfected with a full copy human IL-6 cDNA; D. Hogge, Terry Fox Laboratory, Vancouver, Canada); and 50 ng/mL of Steel factor (SF; Amgen). The methodology and criteria for hematopoietic colony generation and recognition were the same as previously de~cribed.~' The general procedure used for LTC-IC assays has also been described in detail previously." Briefly, test cells were resuspended in long-term medium (an enriched Alpha medium containing 12.5% horse serum, 12.5% FCS, mol/L 2-mercaptoethanol [STI], to which freshly dissolved hydrocortisone sodium hemisuccinate [Sigma] was added just before use to give a final concentration of moVL) and then seeded onto semiconfluent feeder layers of irradiated (80 Gy) mouse marrow-derived fibroblasts that had been genetically engineered to produce human G-CSF, L-3, and SF.3q These LTC-IC assay cultures were then maintained at 37°C and fed weekly by replacement of half of the medium containing half of the nonadherent cells with the same volume of fresh long-term medium. After a total of 6 weeks, the nonadherent cells were removed, washed, and combined with the trypsinized and suspended adherent layer cells. These pooled cells were then plated in methylcellulose assays as described above. The total number of clonogenic cells (BFU-E plus CFU-GM plus CFU-GEMM) present at 6 weeks provides a relative measure of the number of LTC-IC originally present in the test suspension." Limiting dilution experiments have shown that under the conditions used here for LTC-IC detection, on average, one LTC-IC will produce approximately eight clonogenic cells (C.J.E., unpublished observation, August 1995). and this was, therefore, the value used to derive the absolute LTC-IC frequencies reported. In LTC-IC assays where no colonies were detected, the minimum number of LTC-IC that could have been detected was calculated by assuming that one colony had been produced by the entire aliquot of cells evaluated in the final methylcellulose assays. This value (instead of zero) was then used to derive an estimate of the upper limit of the mean 5 SEM number of LTC-IC in groups where one or more values were below the limit of detection. In such cases the mean is indicated as less than x 5 SEM.
RESULTS
Altered CD44 expression on phenorypically dejined populations of primitive CML cells. To compare the patterns of expression of CD44, CD34, and Thy-l on primitive normal 2979 and neoplastic (Ph') CML cells, we isolated various fractions of light-density bone marrow cells from normal individuals and compared their staining profiles with those obtained for cells in the light-density fraction of PB from a series of patients with newly diagnosed CML and high white blood cell (WBC) counts. The choice of this source of CML cells for these comparisons was based on previous data showing that the light-density cells in the PB of patients with chronic phase CML and high WBC counts, on average, will contain a greater than 10-fold increase in all types of leukemic (Ph') progenitors (both clonogenic cells and LTC-IC), such that they approach or even exceed the frequency of the same types of primitive normal cells in the lightdensity fraction of normal BM cell^.^^" Figure 1 
290% of the light-density cells in both normal BM and CML PB were CD44'. In addition, among the CD34' populations present in these samples, no CD" cells were detectable. From these analyses, two additional similarities between normal BM and CML PB were consistently noted. First, the relative proportion of CD34' cells that were also Thy-l' was approximately the same. Second, the proportion of (total) CD34' cells in CML PB expressing very high (1,OOOX background, designated CD44"'), as compared with the proportion expressing intermediate (IOOX background, CD44++), levels of CD44 appeared indistinguishable from those characteristic of the CD34' population in normal BM ( Table 2) . However, in the CML samples, the proportion of Thy-]' cells that were CD44"' was significantly higher than in normal BM (0.4% t 0.1% of CD34' cells in normal BM compared with 1.2% ? 0.2% of CD34' cells in CML PB; P < .01, Student's t test).
In addition, we looked within the entire light-density fraction of normal BM and CML PB, as well as within their respective CD34' subpopulations, for cells expressing exon vl0-containing CD44 isoforms. For this, we used the 2G1 MoAb, which specifically recognizes an epitope present on the extracellular portion of CD44 isoforms containing the amino acids encoded by the v10 exon. In normal BM, 2G1+ cells were relatively rare, comprising from 4% to 8% of the total light-density fraction and s l % of the CD34' cells. In all of the six CML PB samples analyzed, 2GI' cells were much more prevalent (up to 30% of the light-density cell fraction) and included cells that were also expressing CD34 (up to 7%), although there was marked patient-to-patient variability in the proportion of CD34' cells that were also 2G l +. Nevertheless, because of the large elevations in total numbers of light-density myeloid cells in the blood of these patients, these findings suggest that there is a marked increase in the absolute number of 2GI' hematopoietic cells in patients with CML. On the other hand, in both normal BM and CML PB, all of the 2G1' cells appeared to be To determine the nature of the vl0-containing CD44 isoform(s) expressed by 2G1+ cells, RT-PCR was performed. Primers were designed to amplify all vl0-containing CD44 isoforms but to exclude all other sequences lacking this exon. This was achieved by selecting a 5' primer from a region common to all CD44 isoforms and a 3' primer in the last of the alternatively spliced exons (v10). This analysis yielded two major bands of approximately 680 and 480 bp (Fig 3) . These correspond to the expected sizes of the CD44 isoforms RI and R2 (672 and 481 bp, respectively), which have been previously demonstrated in various hematopoietic cells.21 Differential expression of CD44 on different normal progenitor populations. In view of the extensive variation in the level of CD44 expression seen on the CD34+ cells present in normal BM, it was of interest to determine whether any lineage-associated changes in CD44 expression might be demonstrable. To examine this possibility, light-density CD34+ cells from six normal BM samples were sorted according to their expression of very high (+ + +) or intermediate levels (+ +) of CD44 and detectable versus undetectable levels of Thy-l. Cells from each of the four subpopulations thus obtained (shown in Fig 1) were then assayed in both clonogenic and LTC-IC assays. The resultant frequencies of the various progenitor types measured are shown in Table  3 . The greatest enrichment of BFU-E was obtained in the CD44++Thy-I-fraction and, to a lesser extent, in the CD44++Thy-l+ fraction. Very few BFU-E were found in the CD44+++ fractions (either Thy-l+ or Thy-l -; Fig 4) . In contrast, comparing the absolute numbers of colonies recovered, we found that both CFU-GM and LTC-IC were more heterogeneous in their levels of CD44 expression (Table 3 and Fig 4) . Most CFU-GM were Thy-I-, and further separa-2981 tion of these cells according to their level of CD44 expression did not result in a selective enrichment of a subpopulation of Thy-l-CFU-GM. Some (8% ? 4%) CFU-GM were also Thy-1 +. These appeared to be confined primarily to the CD44++ population of CD34+ cells. As found previously, LTC-IC were usually more highly enriched in the Thy-l+ as opposed to the Thy-l-fractions of CD34+ normal BM cells. 33 However, in terms of total LTC-IC yields, a substantial proportion (68% +-13%) of all LTC-IC were Thy-l-. Figure 4 shows a comparison of the relative distribution of each of these normal progenitor types between the CD44" and the CD44+++ fractions. The difference in the ratio of CD44++ to CD44+++ progenitors between CFU-GM (or LTC-IC) and BFU-E was statistically significant ( P < .02 in both cases, Student's t test).
Expression of CD44 on CML progenitors is altered. PB samples from five patients with CML were analyzed to determine the level of expression of Thy-l and CD44 on various primitive leukemic cell populations. The frequencies of CFU-GM and BFU-E in each of the four CD34+ subpopulations defined by differences in Thy-l and CD44 expression (gated as indicated in Fig 2) are shown in Table 4 . The relative recoveries of these progenitors in the CD44++ versus the CD44"' fractions by comparison with normal progenitors are shown in Fig 5. To control for the fact that CML cells might exhibit features unique to circulating and/or activated mobilized progenitors, a series of PB harvests collected after treatment of patients with remission AML or Hodgkin's disease with chemotherapy and administration of G-CSF or GM-CSF and IL-3 were also analyzed. Scatter plots of CD44 versus Thy-l expression by the CD34+ cells in these leukapheresis samples were not noticeably different (data not shown) from those seen for normal BM (Fig 1) or CML PB (Fig 2) . Similar CD44 gates were, therefore, used to compare the distribution of different progenitor types amongst the two subpopulations of interest (defined by their levels of CD44 expression) in the CML PB and mobilized normal PB samples. The results of these studies are shown in Table 5 and in Fig 5. The analyses of the CML samples revealed a number of interesting findings. First, as can be seen in Table 4 , both Thy-l+ and Thy-l ~ BFU-E and CFU-GM were readily and consistently detected in CML PB. Although genotyping studies of the colonies produced by these sorted progenitors were not performed, it is unlikely from the number originally present in the samples used ( Table 1 ) that any of these sorted progenitors contained a significant proportion of normal cells. Moreover, in a more extensive analysis of CD34+ subpopulations of CML progenitors reported elsewhere,"' the presence of a significant population of Ph+ Thy-1 + CFU-GM in CML PB has been directly demonstrated. Second, the number of LTC-IC in the CML PB samples studied was often below the level of detectability. More recent studies4' have shown that cryopreservation selectively kills Ph+ LTC-IC, which would explain the unexpectedly low yield of LTC-IC obtained in this study where most samples had been frozen before use. Finally, as shown in Fig 5, the proportion of CFU-GM found in the CD44+++ fraction of CD34+ CML Patient numbers l a and l b refer to fresh and thawed cells from the same original sample (see Table 1 ).
CFU-GM
t For the population analyzed.
PB cells was consistently and significantly ( P < .01) elevated by comparison to CFU-GM in normal BM. Interestingly, this was not true for the BFU-E present in CML PB. Moreover, the alteration in CD44 expression by CML CFU-GM was not found to be a general feature of normal CFU-GM that had been mobilized into the circulation, because the ratio of CD44++ to CD44+++ CFU-GM in leukapheresis harvests was not different from that characteristic of CFU-GM in normal BM.
DISCUSSION
The production of different CD44 isoforms in conjunction with variable degrees of their glycosylation and chondroitin sulfate attachment is believed to explain the diversity of adhesion-dependent processes in which CD44 has been implicated."." In this study, we have obtained further evidence that CD44 may be involved in the regulation of early stages of hematopoiesis based on the demonstration of differentiation-and transformation-associated changes in the expression of this gene product on primitive normal and CML cells. Analysis of the CD34+ population in normal BM and CML PB indicated that CD44-cells are not present at a detectable level within this fraction, in contrast with the total light-density cell fraction, of which a small percent (up to approximately 10%) may be identified as CD". Functional studies showed that the LTC-IC in normal marrow express intermediate to very high levels of CD44, thus mirroring the heterogeneous pattern of CD44 expression also exhibited by normal CFU-GM. In contrast, BFU-E in normal BM represent a more homogenous population of cells in terms of their pattern of CD44 expression. It will be interesting to determine whether the subset of CFU-GM expressing very high levels of CD44 are those that are able to bind immobilized hyaluronan4' or that cooperate with the cr4/3, integrin in binding to the C-terminal heparin-binding domain of fibronectin.4' Kansas et all4 also have reported changes in CD44 expression as hematopoietic cells mature, although in their studies, CD44 was seen to be downregulated at later stages of myeloid and erythroid cell maturation. The pattern of CD44 expression on primitive CML cells was found to differ in two respects from that exhibited by normal BM or mobilized PB cells. First, a significantly larger proportion of CML CFU-GM were found to express CD44 at a very high level, and second, a subset of CD34+ cells expressing an exon vl0-containing CD44 isoform(s) that was not detectable in normal BM could be readily detected in all CML PB samples analyzed. Because all normal samples used in this work were frozen, the changes in the pattern of CD44 expres- sion on CML cells could not be attributed to a general freezethaw artefact. Whether they may contribute to the abnormal adhesive properties previously described for CML cells remains to be established. The mechanism(s) underlying the increased expression of CD44 on CML CFU-GM as well as the increased expression of exon vl0-containing CD44 isoform(s) on more mature CML cells, including some within the CD34+ population, is also unknown. In particular, it is not clear whether these increases are accompanied by concomitant changes in the expression of other CD44 isoforms. Activation is one of multiple mechanisms of CD44 isoform expression described in different cell types.I6 The increase observed here in expression of CD44 on CML CFU-GM may, therefore, be related to their constitutively activated for example, through BCR-ABL stimulation of the ras pathway as a result of the association of p210BCR-ABL with GRB-~/SOS?'~' The product of the BCR-ABL gene has also been found to inhibit p120 GAP which would favor the formation of GTP-bound ras and, hence, its accumulation in an activated form. The results of BCR-ABL transfection experiments have also implicated p210BCR-ABL in the constitutive activation of ras,48 and several studies have indicated that ras activation may alter CD44 expression, by modulating CD44 promotor activity as well as via mechanisms that control CD44 transcript s p l i~i n g .~~,~~~~~ It is interesting to note that modulations of CD44 expression were not observed in cells obtained from patients treated with IL-3 in spite of the described ability of this cytokine to transiently activate the ras pathway." Collectively, these findings suggest multiple mechanisms by which the observed changes in CD44 expression seen at different levels of granulopoiesis in CML could be related to the expression of the BCR-ABL gene in these cells, although they do not explain why such changes should be restricted to the granulopoietic lineage.
The identification of a small subset of maturing myeloid cells in normal BM that appear to express different exon vl0-containing isoforms of CD44 is concordant with previous reports demonstrating that a change in CD44 isoform expression is not uniquely associated with malignant transf o r m a t i~n *~.~~ but may be more closely correlated with changes in properties that also occur during the development or functional activation of normal
The observed increase in expression of exon vl0-containing CD44 isoform(s) on CML cells could simply reflect a selective amplification in CML of a cell type that normally expresses these isoforms. Alternatively, it could reflect a direct effect of malignant transformation on cells that would not normally express exon v10. Support for the latter possibility has been recently suggested by the finding of alterations in CD44 expression on primary cells from patients with other types of (acute) myeloid le~kemia.~' In summary, we have documented the presence of CD44 on LTC-IC in normal human BM and have provided evidence of a heterogeneity in the level of the CD44 expressed on these very primitive cells that is also shared by normal CFU-GM. In contrast, most normal BFU-E express, on average, a lower level of CD44. We have also provided evidence for the expression of different vl0-containing CD44 isoforms in normal human marrow cells. In CML, there is a disproportionate increase in the type of CFU-GM that express very high levels of CD44. These findings, taken together with the abnormal production by CD34' CML cells of exon vl0-containing isoform(s) of CD44, suggest that the control of CD44 mRNA production and processing may be influenced by both normal differentiation mechanisms and those that mediate leukemic transformation.
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